Thymic carcinoma medical therapy

Jump to navigation Jump to search

Thymic Carcinoma Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thymic carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Thymic carcinoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Thymic carcinoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thymic carcinoma medical therapy

CDC on Thymic carcinoma medical therapy

Thymic carcinoma medical therapy in the news

Blogs on Thymic carcinoma medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Thymic carcinoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [3]

Overview

The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-based chemotherapy may be required.[1]

Medical Therapy

Medical treatment options for thymic carcinoma include the following:[1]

  • Sunitinib[2]
  • Gemcitabine
  • Docetaxel
  • Checkpoint inhibitors
  • Radiation

Multimodality approach, such as:

  • Surgical resection
  • Radiation therapy
  • Cisplatin-based chemotherapy

References

  1. 1.0 1.1 National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.
  2. Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ; et al. (2015). "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial". Lancet Oncol. 16 (2): 177–86. doi:10.1016/S1470-2045(14)71181-7. PMC 4401497. PMID 25592632.